Microsure announced today that it received CE mark approval for its MUSA-3 surgical robot and named Alex Joseph as CEO.
Joseph succeeds Iwan van Vijfeijken as the Eindhoven, the Netherlands-based company can now bring MUSA-3 into clinical use in Europe. The company said its CE mark reflects its transition from product development to a clinical medical device business.
Microsure designed MUSA-3 to assist surgeons during open super-microsurgical procedures by downscaling and stabilizing hand movements. It supports super-micro-anastomosis on small anatomical structures. These include lymphatic ducts, blood vessels and nerves. The company said it has applications in free flap surgery, lymphatic surgery and peripheral nerve surgery.
MUSA-3 offers enhanced dexterity, a wider workspace and tremor reduction for enhanced precision. It integrates seamlessly with surgeons’ existing preferred micro-instruments from different brands. The system’s adaptability also enables its uses in a wide range of surgical procedures.
With MUSA-3, Microsure aims to deliver high-precision, super-microsurgical robotics to go beyond human capabilities. Microsurgical robotics is an interesting subsection of the surgical robotics space, with companies like Medical Microinstruments also recently making waves.
(Learn more about the surgical robotics space in our MassDevice Surgical Robotics Special Report. Download the report for free here.)
As the company can bring MUSA-3 to the European market, its leadership transition reflects the move toward the clinical phase.
Microsure said Joseph played a central role in the development of MUSA-3. The company says he brings deep expertise in surgical robotics, clinical environments and regulated medical device development.
Looking forward, the company now aims to focus on clinical adoption, evidence generation and building the foundation for broader commercialization.
“As I step into the role of CEO, Microsure is entering a new phase. With the CE mark now achieved, our focus is on generating clinical evidence and demonstrating the value of our technology in practice,” said Alex Joseph.
